2020年5月25日 · Background: LAM-002 is a selective inhibitor of PIKfyve that disrupts lysosomal homeostasis, inducing cytotoxicity in B-cell lymphoma models as monotherapy or with anti …

Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma. Adenosine …

2014 ASCO Annual Meeting A patient-derived xenograft (PDX) platform to optimize omics-driven precision medicine in bladder cancer . First Author: Chong-xian Pan

2025年3月7日 · Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or …

Welcome to the new ASCO.org! ASCO.org has a new look and feel, making it easier than ever to find premier oncology research from ASCO Meetings and Journals, and offering customized …

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 …

Take advantage of early registration rates and secure your spot at the global oncology event of 2025! Don’t miss out—the ASCO Annual Meeting is The Place to Be.

2020年1月30日 · AI Therapeutics ‘ lymphoma candidate LAM-002 was identified by the company’s artificial intelligence -based platform — called Guardian Angel — as a possible …

2023年5月31日 · Deep learning AI algorithms are used to identify the gastric cancer signature. Results from testing and validation of the identified routine blood signature using a Big Clinical …

American Society of Clinical Oncology - Photo Gallery